1
|
Shah AH, Rivas S, Doucet-Ohare T, Govindarajan V, DeMarino C, Ampie L, Banasavadi-Siddegowda Y, Maric D, Suter R, Lee MH, Zaghloul KA, Walbridge S, Garcia-Montojo M, Steiner J, Johnson K, Gilbert MR, Heiss JD, Nath A. 379 Human Endogenous Retrovirus-K (HML-2) Contributes to a Unique Stem-Cell Niche in Glioblastoma. Neurosurgery 2023. [DOI: 10.1227/neu.0000000000002375_379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/18/2023] Open
|
2
|
Shah A, Govindarajan V, Doucet-O'Hare T, Rivas S, Ampie L, DeMarino C, Banasavadi-Siddegowda Y, Zhang Y, Johnson K, Almsned F, Gilbert M, Heiss J, Nath A. EPCO-33. DIFFERENTIAL EXPRESSION OF AN ENDOGENOUS RETROVIRAL ELEMENT [HERV-K(HML-6)] IS ASSOCIATED WITH REDUCED SURVIVAL IN GLIOBLASTOMA PATIENTS. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac209.467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
INTRODUCTION
Comprising approximately 8% of our genome, Human Endogenous RetroViruses (HERVs) represent a class of germline retroviral infections that are regulated through epigenetic modifications. In cancer cells, which often have epigenetic dysregulation, HERVs have been implicated as potential oncogenic drivers. However, their role in gliomas is not known.Given the link between HERV expression in cancer cell lines and the distinct epigenetic dysregulation in gliomas, we utilized a tailored bioinformatic pipeline to characterize and validate the glioma retrotranscriptome and correlate HERV expression with locus-specific epigenetic modifications.Method:A custom workflow was used to quantify HERV expression in our cell lines of interest. Cell-line methylation was quantified using a custom script. We generated primers specific for the Human endogenous Mouse mammary tumor (MMTV)-Like virus 6 (HML-6). Visualization of RNA transcripts was performed using RNA-scope. Clinical data was obtained using the R package, TCGABiolinks.
RESULTS
The A172 cell line had significantly higher mean overall HERV expression relative to the M059J and H4 cell lines (p< 0.0001 for both). A172 cells had significantly lower mean number of CpG islands relative to M059J cells and H4 cells (p< 0.0001 for both). There was a significant inverse correlation between mean beta value and FC HERV expression (R=-0.57, p=0.01). qPCR confirmed robust expression of the HML-6 locus in cell culture and neurospheres. Elevated ERVK3-1 expression was associated reduced survival among IDHwt GBM patients (18.3 vs. 15.1 months, p=0.039). This was preserved among IDH mutant (IDHm) GBM as well (17.9 months vs. 14.0 months, p=0.0088).
CONCLUSION
In gliomas, HERV expression correlates with loss of DNA methylation at HERV loci. HML-6 is overexpressed in highly invasive glioblastoma cell lines and patient-derived neurospheres. We have demonstrated a potential survival detriment associated with elevated expression of the HML-6 product, ERVK3-1.
Collapse
Affiliation(s)
- Ashish Shah
- University of Miami Miller School of Medicine , Miami, FL , USA
| | | | - Tara Doucet-O'Hare
- National Institutes of Health, National Cancer Institute (NCI), Center for Cancer Research (CCR), Neuro-Oncology Branch (NOB) , Bethesda, MD , USA
| | - Sarah Rivas
- Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health , Bethesda, MD , USA
| | - Leo Ampie
- National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States , Bethesda, MD , USA
| | - Catherine DeMarino
- National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States , Bethesda, MD , USA
| | - Yeshavanath Banasavadi-Siddegowda
- National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States , Bethesda, MD , USA
| | - Yong Zhang
- National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS), Bioinformatics Section , Bethesda, MD , USA
| | - Kory Johnson
- National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS), Bioinformatics Section , Bethesda, MD , USA
| | - Fahad Almsned
- National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS), Bioinformatics Section , Bethesda, MD , USA
| | - Mark Gilbert
- Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, MD , USA
| | - John Heiss
- National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States , Bethesda, MD , USA
| | - Avindra Nath
- National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States , Bethesda, MD , USA
| |
Collapse
|
3
|
Rivas S, Rivera-Caraballo K, Murphy S, Otani Y, Shelbourn A, Ampie L, Maric D, Walbridge S, Shah A, Yan Y, Yoo JY, Heiss J, Kaur B, Banasavadi-Siddegowda Y. EXTH-76. PRMT5 INHIBITION SENSITIZES GLIOBLASTOMA NEUROSPHERES TO TEMOZOLOMIDE. Neuro Oncol 2022. [PMCID: PMC9660776 DOI: 10.1093/neuonc/noac209.874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
INTRODUCTION
The median survival of Glioblastoma (GBM) patients is less than two years with the standard of care of maximal surgical resection, radiation, and temozolomide (TMZ) chemotherapy. Protein Arginine Methyltransferase 5 (PRMT5), which regulates cellular functions by symmetrically di-methylating arginine residues, is overexpressed in GBM. Inhibiting PRMT5 induces apoptosis in differentiated and senescence in stem-like GBM tumor cells. We inhibited PRMT5 in GBM neurospheres to determine if PRMT5 inhibition would enhance TMZ’s antitumor effect.
METHODS
We depleted PRMT5 activity, in vitro, using target-specific siRNA or LLY-283 and combined these with TMZ treatment. We evaluated the antitumor effect of this combination using cell viability assay, cell cycle analysis, apoptosis assay, and western blot.
RESULTS
TMZ reduced the viability of GBMNS with PRMT5 knockdown significantly more than the viability of PRMT5 intact GBMNS. The combination of TMZ and PRMT5 knockdown elevated the expression of cleaved caspase 3 and caspase3/7 indicating that PRMT5 knockdown enhanced the apoptotic effects of TMZ. Cell cycle analysis showed that depleting PRMT5 abrogated TMZ-induced G2/M cell cycle arrest. Further, treatment of PRMT5-depleted GBMNS with TMZ increased ɣ-H2AX expression compared PRMT5 intact GBMNS treated with TMZ, suggesting that PRMT5 depletion enhanced TMZ-induced DNA damage. PRMT5 knockdown also inhibited the symmetric di-methylation of RUVBL1 that is required for homologous recombination repair of TMZ treatment-related DNA damage.
CONCLUSION
Overall, PRMT5 inhibition sensitized GBMNS to TMZ and enhanced TMZ-related DNA damage and cytotoxicity. These findings support further development of this potential therapeutic combination.
Collapse
Affiliation(s)
- Sarah Rivas
- Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health , Bethesda, MD , USA
| | - Kimberly Rivera-Caraballo
- Department of Neurosurgery, University of Texas Health Science Center at Houston , Houston, TX , USA
| | - Sara Murphy
- Department of Neurosurgery, University of Texas Health Science Center at Houston , Houston, TX , USA
| | - Yoshihiro Otani
- Department of Neurosurgery, University of Texas Health Science Center at Houston , Houston, TX , USA
| | - Allison Shelbourn
- Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health , Bethesda, MD , USA
| | - Leo Ampie
- National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States , Bethesda, MD , USA
| | - Dragan Maric
- Flow and Imaging Cytometry Core Facility, National Institute of Neurological Disorders and Stroke, National Institutes of Health , Bethesda, MD , USA
| | - Stuart Walbridge
- Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health , Bethesda, MD , USA
| | - Ashish Shah
- Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health , Bethesda, MD , USA
| | - Yuanqing Yan
- Department of Neurosurgery, University of Texas Health Science Center at Houston , Houston, TX , USA
| | - Ji young Yoo
- Department of Neurosurgery, University of Texas Health Science Center at Houston , Houston, TX , USA
| | - John Heiss
- Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health , Bethesda, MD , USA
| | - Balveen Kaur
- Department of Neurosurgery, University of Texas Health Science Center at Houston , Houston, TX , USA
| | - Yeshavanath Banasavadi-Siddegowda
- National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States , Bethesda, MD , USA
| |
Collapse
|
4
|
Shah A, Rivas S, Doucet-Ohare T, Govindarajan V, DeMarino C, Ampie L, Banasavadi-Siddegowda Y, Maric D, Garcia-Montojo M, Suter R, Lee MH, Walbridge S, Zaghloul K, Steiner J, Johnson K, Gilbert M, Heiss J, Nath A. STEM-07. DEFINING THE ROLE OF HUMAN ENDOGENOUS RETROVIRUS-K (HML-2) IN THE GLIOBLASTOMA STEM-CELL NICHE. Neuro Oncol 2022. [PMCID: PMC9660633 DOI: 10.1093/neuonc/noac209.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Human Endogenous Retrovirus (HERV) are ancestral viral relics that comprise nearly 8% of the human genome. Although silenced in normal tissues, the most recently integrated provirus HERV-K (HML-2) can be pathologically reactivated in certain cancers. Here, we report pathological expression of HML-2 transcripts in human malignant gliomas in cerebrospinal fluid (HERV-K DNA/RPP30=35.2±8.8 vs 23.1±6.7, n=18, p=0.02) and tumors (HERV-K RNA/HPRTmean=1.15±0.2 vs. 0.5±0.2, p=0.01, n=20) compared to epilepsy controls. Aberrant HML-2 expression corresponded to a unique stem-cell niche using multivoxel automated segmentation. Using a tailored single-cell RNA sequencing pipeline to detect retrotransposons, we identified glioblastoma cellular populations with elevated HML-2 transcripts in neural progenitor-like cells that can drive cellular plasticity (ANOVA, multiple-testing correction, p< 0.001). Using CRISPR technology, we demonstrate that HML-2 is critical to maintenance of glioblastoma stemness and tumorigenesis in both glioblastoma neurospheres and intracranial orthotopic murine models (OS: 26 days vs. 18.6, p=0.0008, n=20). Downregulation of HERV-K using CRISPRi reduces the glioblastoma neurosphere formation (2-way ANOVA, p< 0.0001). and HERV-K env, Polymerase, OCT4 and Nestin transcripts (2-way ANOVA p< 0.001). Using Chromatin Immunoprecipitation, we determined that this interaction in gliomas is likely mediated by the nuclear transcription factor OCT4 which binds to an HML-2 specific Long-Terminal Repeat (LTR5Hs). Moreover, using Transmission Electron Microscopy, we discovered that some glioma stem-cells form immature retroviral virions in glioblastoma. Inhibiting HML-2 expression with nucleoside reverse transcriptase inhibitors reduces extracellular reverse transcriptase (One-way ANOVA, p< 0.05), tumor viability (IC50=75.8-123.1 uM), and pluripotency (One-way ANOVA, p< 0.01). Our results suggest that HML-2 is overexpressed in the cancer stem-cell niche of glioblastoma. Since persistence of glioblastoma stem-cells is considered responsible for treatment resistance and recurrence, HML-2 may serve as a unique therapeutic target in glioblastoma.
Collapse
Affiliation(s)
| | - Sarah Rivas
- Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health , Bethesda, MD , USA
| | | | | | - Catherine DeMarino
- National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States , Bethesda, MD , USA
| | - Leo Ampie
- National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States , Bethesda, MD , USA
| | | | | | | | - Rob Suter
- Georgetown University , Bethesda, MD , USA
| | | | | | | | | | | | - Mark Gilbert
- Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, MD , USA
| | | | - Avindra Nath
- National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States , Bethesda, MD , USA
| |
Collapse
|
5
|
Jaime-Ramirez A, Bolyard C, Meisen W, Dmitrieva N, Banasavadi-Siddegowda Y, Kaur B. NT-12 * IMPACT OF HUMANIZED CHONDROITINASE ABC ON OV THERAPY FOR INTRACRANIAL TUMORS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou265.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|